Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.

Aglaya G Iyevleva Natalia V Mitiushkina Nina A Karaseva Sergey V Orlov Larisa N Volodina Yulia E Kulikova Alexandra M Lozhkina Alexandr O Ivantsov Vladislav I Tiurin Alexandr V Togo Evgeny N Imyanitov

J Thorac Oncol

N.N. Petrov Institute of Oncology, St. Petersburg, Russia, St.Petersburg Pediatric Medical Academy, St.Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia City Oncological Hospital, St. Petersburg, Russia Institute of Pulmonology, St. Petersburg, Russia Regional Oncological Hospital, Ryazan, Russia Institute of Pulmonology, St. Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia St. Petersburg Pediatric Medical Academy, St.Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia, St.Petersburg Pediatric Medical Academy, St.Petersburg, Russia, I.I. Mechnikov North-Western Medical University, St. Petersburg, Russia.

Published: April 2014

Download full-text PDF	Source
http://dx.doi.org/10.1097/JTO.0000000000000106	DOI Listing

Publication Analysis

Top Keywords

lung carcinomas

carcinomas egfr

egfr exon

exon insertions

insertions sensitive

sensitive gefitinib

gefitinib treatment

lung

egfr

exon

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!